Pay in 4 interest-free payments of $14.75 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
3 μM) but not p110α/p85α PI3K (IC50>100 μM)
): Indication: For the treatment of primary biliary cholangitis [Internet]
Similarly in the proliferation assay
PFI-2 was used at 1 µM in vitro
It was licensed to Glaxo in 1990 and approved in the US in 1999
MGL-3196 - CAS# 920509-32-6 PTO-253 3 μM) but not p110α/p85αMGL 3196, CAS No. 920509 32 6, also known as Resmetirom, is a potent and highly selective thyroid hormone receptor agonist in clinical trials for the treatment of dyslipidemia. The beneficial effects of thyroid hormone (TH) on lipid levels are primarily due to its action at the thyroid hormone receptor (THR ) in the liver, while adverse effects, including cardiac effects, are mediated by thyroid hormone receptor (THR ). Product information CAS Number:
US$ 22.00
US$ 24.00
US$ 14.00
US$ 24.00
US$ 24.00
US$ 24.00
US$ 16.00
US$ 14.00
US$ 14.00
US$ 24.00
US$ 28.00